Dr. Satish Sharma

About

Dr. Satish Sharma is a Consultant in the Department of Medical Oncology with eight years of dedicated experience in the field. His expertise spans across Chemotherapy, Targeted Therapy, Immunotherapy, and Multidisciplinary Treatment. Dr. Sharma’s professional achievements include qualifying in the Zonal Round of TYSA in Medical Oncology and clearing the ECMO examination. He has actively participated in numerous national and international conferences, including ASCO, contributing to advancements in oncology care. Dr. Sharma’s research contributions include publications like “Impact of Nationwide Lockdown on Cancer Care during COVID-19: A Retrospective Analysis from Western India” (ASCO 2022), “Tumour Induced Osteomalacia” (ASEAN Endocrine Journal, 2016), and “Myocardial Sarcoidosis: Complete Remission on PET” (submitted to NEJM, 2017). Additionally, his work on “Mesenteric Leiomyosarcoma: Long-Term Survival Possible” and “Interstitial Lung Disease in Rheumatoid Arthritis: A Prospective Study at a Tertiary Care Center” (Indian Journal of Chest Disease & Allied Sciences, 2022) reflects his commitment to advancing medical knowledge. Notably, Dr. Sharma has documented a rare case in “Successful Rechallenge of Bevacizumab After Grade 4 Bevacizumab-Induced Hypertension in a Case of Carcinoma Ovary: Is Rechallenging an Option?”, showcasing his innovative approach to oncology treatment.

Areas Of Expertise

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Multidisciplinary Treatment

Experience

8+ years of work experience with the Department of Oncology.

Achievements

• Zonal Round TYSA, Medical Oncology Qualified ECMO exam
• Took part in many National and International conferences ( including ASCO)

Publications

“Impact of nationwide lockdown on cancer care during COVID-19 – pandemic: A retrospective analysis from western India” – ASCO- 2022 “Tumour Induced Osteomalacia” in ASEAN Endocrine Journal – 2016 “Myocardial Sarcoidosis- Complete remission on PET” sent to NEJM- 2017 “Mesenteric Leiomyosarcoma – long term survival possible” and “Interstitial Lung Disease in Rheumatoid Arthritis; A Prospective Study at a Tertiary Care Center” in The Indian journal of chest disease & allied science 2022 “Successful rechallenge of bevacuzimab after grade 4 bevacuzimab induced hypertension in a case of carcinoma ovary, is rechallenging an option?” – A rare case